Lomudal Augndropar, lausn 20 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lomudal augndropar, lausn 20 mg/ml

stada arzneimittel ag - sodium cromoglicate - augndropar, lausn - 20 mg/ml

Zavicefta Evrópusambandið - íslenska - EMA (European Medicines Agency)

zavicefta

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - sýklalyf fyrir almenn nota, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Flutiform (Affilia) Innúðalyf, dreifa 125 míkróg/5 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

flutiform (affilia) innúðalyf, dreifa 125 míkróg/5 míkróg

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 125 míkróg/5 míkróg

Flutiform (Affilia) Innúðalyf, dreifa 250 míkróg/10 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

flutiform (affilia) innúðalyf, dreifa 250 míkróg/10 míkróg

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 250 míkróg/10 míkróg

Flutiform (Affilia) Innúðalyf, dreifa 50 míkróg/5 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

flutiform (affilia) innúðalyf, dreifa 50 míkróg/5 míkróg

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 50 míkróg/5 míkróg

Spiriva Respimat Innöndunarlausn 2,5 míkróg/skammt Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

spiriva respimat innöndunarlausn 2,5 míkróg/skammt

boehringer ingelheim international gmbh* - tiotropii bromidum inn - innöndunarlausn - 2,5 míkróg/skammt

Budesonide Alvogen (Budesonide Teva) Dreifa í eimgjafa 0,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

budesonide alvogen (budesonide teva) dreifa í eimgjafa 0,5 mg/ml

alvogen ehf. - budesonidum inn - dreifa í eimgjafa - 0,5 mg/ml

Zinforo Evrópusambandið - íslenska - EMA (European Medicines Agency)

zinforo

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - sýklalyf fyrir almenn nota, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Pulmicort Dreifa í eimgjafa 0,125 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pulmicort dreifa í eimgjafa 0,125 mg/ml

astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,125 mg/ml

Pulmicort Dreifa í eimgjafa 0,25 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pulmicort dreifa í eimgjafa 0,25 mg/ml

astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,25 mg/ml